HTG Molecular Diagnostics (HTGM) Tops Q2 EPS by 11c

HTG Molecular Diagnostics (NASDAQ: HTGM) reported Q2 EPS of ($0.54), $0.11 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $1.49 million versus the consensus estimate of $2.35 million.

For earnings history and earnings-related data on HTG Molecular Diagnostics (HTGM) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance